Harvard Medical School Faculty Advances Drug Safety Research with IBM Business Analytics

IBM (NYSE: IBM) announced that faculty from Harvard Medical School and Brigham & Women's Hospital will use IBM business analytics technology at the core of new research that examines the effectiveness of prescription drugs and spots potential safety issues.

Harvard Medical research teams are conducting advanced pharmacoepidemiology studies that look at the effects of drugs in large numbers of people based on insurance claims data. Using an IBM Netezza data warehouse appliance, the research teams will expand its studies to analyze data from millions of de-identified patient records with the aim to develop new data-intensive drug safety research methods.

Pharmacoepidemiology research is designed to answer important questions such as which anti-inflammatory drugs carry a risk of heart attack, what osteoporosis medications are most often used with good results, or how cost-effective are some drugs in treating mental health disorders.

"We wanted a computing platform with massive analytics power, but was extremely simple to administer," said Dr. Sebastian Schneeweiss, Associate Professor of Medicine, Harvard Medical School and Vice Chief of the Brigham & Women's Hospital Division of Pharmacoepidemiology and Pharmacoeconomics. "As global healthcare evolves toward a learning healthcare system with a need for ongoing comparative effectiveness and safety research integrated in routine care, it is imperative that research methods evolve in parallel. IBM Netezza will accelerate our ability to devise, test and publish new computationally intensive algorithms applied to ever larger longitudinal healthcare databases that we hope will become the gold standard for researchers globally."

Dr. Schneeweiss is the principal investigator of the AHRQ-funded DEcIDE Methods Center and Co-Chair of the Methods Core of the FDA-funded Mini Sentinel project. The study of patterns of health and illness associated with prescription drugs over long periods of time help determine which treatments are proven to have the best outcomes, and which are most viable for specific populations of patients. IBM Netezza business analytics technology will help Dr. Schnieeweiss' research team establish newer and more sophisticated analytic algorithms that can be automated to produce more accurate results.

"Our research lab is focused on the best ways to automate the continuous evaluation of the safety of medications, and we require fast systems to assemble and analyze data,” said Dr. Jeremy Rassen, Assistant Professor of Medicine at Harvard Medical School. “IBM Netezza puts us ahead of the curve, including capabilities for parallelized in-database analytics. We have already seen orders of magnitude performance improvement, without the use of any database administrator time, and system maintenance is done by our researchers and analysts."

Another area of research for Harvard Medical will be health economics and outcomes research (HEOR). Once the effectiveness of medications is established, pharmaceutical companies and health insurers have teams of HEOR analysts to demonstrate the value of new medical products for pricing and coverage decisions to provide higher quality of care. Intelligently mining claims data with a powerful analytics platform like IBM Netezza is often the best and fastest way to answer questions about the most effective therapies.

"The ability to glean insight and act on the analysis of massive amounts of claims data will help Harvard Medical School extend its reputation as one of the largest and most respected medical research organizations in the world," said Arvind Krishna, general manager, IBM Information Management.

About IBM
For information about IBM Netezza, please visit: www.netezza.com

For Information on IBM Information Management, please visit: http://www.ibm.com/software/data/information-on-demand/

Most Popular Now

A step closer to cancer precision medicine

Researchers from the Faculty of Medicine and the Institute for Molecular Medicine (FIMM) at the University of Helsinki have developed a computational model, Combined Esse...

Artificial Intelligence algorithm can learn the la…

Artificial Intelligence can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of resea...

Bayer and Dewpoint Therapeutics partner to researc…

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement worth up to ...

Bristol-Myers Squibb and Pfizer announce randomize…

The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRi...

Bristol-Myers Squibb completes acquisition of Celg…

Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all governmen...

Amgen and the Duke Clinical Research Institute ann…

Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) announced plans to initiate the Cardiovascular Multi-dimensional Observational Inves...

Statins not associated with memory or cognition de…

Given consumer concern that statins may be associated with memory or cognitive decline, a new study published today in the Journal of the American College of Cardiology m...

Novartis announces new strategy to provide innovat…

Novartis announced a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest unders...

New advances in the treatment of advanced lung can…

The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic an...

Unique case of disease resistance reveals possible…

Defying the odds, an individual at high risk for early-onset Alzheimer's disease remained dementia-free for many years beyond what was anticipated. A study funded in part...

Amgen completes acquisition of Otezla® (apremilast…

Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for mo...

Protein could offer therapeutic target for pancrea…

A protein that drives growth of pancreatic cancer, and which could be a target for new treatments, has been identified by researchers at the Crick. The study, published i...